medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Testing the association between tobacco and cannabis use and cognitive functioning: Findings from an observational and Mendelian randomization study

Liam Mahedy[1,2,3] (Ph.D.), Robyn Wootton[1,2,3] (Ph.D.), Steph Suddell[1,2,3] (MSc), Caroline Skirrow[1,4], (Ph.D.), Matt Field[5] (Ph.D.), Jon Heron[6] (Ph.D.), Matthew Hickman[6] (Ph.D.), Marcus R. Munafò[1,2,3] (Ph.D.)

Affiliations

[1]School of Psychological Science, University of Bristol, Bristol, UK.

[2]MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

[3]National Institute for Health Research Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK.

[4]Cambridge Cognition, Cambridge, UK.

[5]Department of Psychology, University of Sheffield, Sheffield, UK.

[6]Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Corresponding author: Liam Mahedy, School of Psychological Science, University of Bristol, 12a Priory Road, Bristol, UK, BS8 1TU.

Tel: +44 (0) 117 33 10616; Email: liam.mahedy@bristol.ac.uk

Key words: ALSPAC, cannabis, tobacco, cognition, longitudinal latent class analysis, Mendelian randomization.

Word count: 4,032 (excluding Abstract, Figures, Tables and References)

CC-BY 4.0 This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Abstract

Background: Although studies have examined the association between tobacco and cannabis use in adolescence with subsequent cognitive functioning, study designs are usually not able to distinguish correlation from causation.

Methods: First, separate patterns of tobacco and cannabis use were derived using longitudinal latent class analysis based on measures assessed on five occasions from ages 13 to 18 years in a large UK based population cohort (ALSPAC). Cognitive functioning measures comprised working memory, response inhibition, and emotion recognition assessed at 24 years of age. One- and two-sample Mendelian randomization, methods for testing causal inference using genetic variants as proxies for an exposure of interest, were used to examine the causal relationship between smoking initiation/lifetime cannabis use, and subsequent cognitive functioning in ALSPAC.

Results: We found evidence of a relationship between tobacco and cannabis use and diminished cognitive functioning for each of the outcomes in the observational analyses. The clearest evidence demonstrated a dose-response relationship between tobacco use and working memory suggesting late-onset regular tobacco smokers (*b*=-0.29, 95%CI=-0.45 to -0.13), early-onset regular smokers (*b*=-0.45, 95%CI=-0.84 to -0.05), and early-onset regular cannabis users (*b*=-0.62, 95%CI=-0.93 to -0.31) performed worse on this task compared to individuals with a very low probability of using tobacco/cannabis. Mendelian randomization analyses were imprecise and did not provide additional support for these results.

Conclusions: Overall, there was some evidence to suggest that adolescent tobacco and cannabis use were associated with diminished cognitive functioning. Better powered genetic studies are required to determine whether these associations are causal.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

INTRODUCTION

Tobacco and cannabis use during adolescence, when the brain is still developing and undergoing considerable structural and function changes (1), is a major public health concern. The association between adolescent tobacco and cannabis use and subsequent cognitive functioning has received particular attention because certain cognitive functions (e.g. working memory, response inhibition, and emotion recognition) do not peak until early adulthood (2–5) in parallel with maturation of the prefrontal cortex (6,7). Due to the prolonged neurodevelopmental period and the potential for the endocannabinoid and nicotinic cholinergic signalling systems to be involved in altering development (8,9), it is plausible that tobacco and cannabis use during this potentially critical period could play a role in disrupting normal brain development (10–13). Nonetheless, there is still uncertainty regarding the nature of the association between tobacco and cannabis use and neurocognitive function.

A recent review of prospective studies of the association between cannabis use and cognition in young people (14) highlighted an association between cannabis use and neuropsychological decline (15,16). However, these studies often fail to control for neurocognitive measures prior to cannabis use (17,18) and associations were largely found for the heaviest cannabis users and were often attenuated when potential confounders (e.g. other forms of substance use) were included (16,19). A recent study (20), using a co-twin design (allowing for the disentanglement of shared environmental and genetic factors), assessed IQ prior to cannabis initiation and found insufficient evidence to suggest cannabis use was associated with decline in general IQ. Findings from two recent longitudinal studies of adolescents (21,22) using a repeated measures design suggest that the association between cognitive functioning and cannabis use could be bidirectional.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

The direction of association between tobacco and cognitive functioning is also unclear as there is a lack of epidemiological studies that have prospectively examined this relationship. Evidence from animal studies suggests that nicotine exposure may have more deleterious developmental effects during adolescence, when the brain is thought to be more vulnerable (23). Furthermore, human studies suggest that nicotine has a more potent effect when consumed in late adolescence compared to in adulthood (24). One small prospective study (*n*=112, aged between 17 to 21 years) found that current smokers performed worse than non-smokers on a variety of cognitive assessments including language related IQ and working memory while controlling for earlier cognitive measures and other substance use (25). Finally, one large study (*n*~20,000) on Israeli male soldiers (26) found a dose-response relationship between number of cigarettes smoked and lower general cognitive ability compared to non-smokers. They also found diminished cognitive functioning in individuals who started starting smoking after 18 years of age.

In an effort to strengthen the evidence, we used data from the Avon Longitudinal Study of Parents and Children, a large UK prospective birth cohort, to investigate whether patterns of adolescent tobacco and cannabis use were prospectively associated with cognitive functioning at 24 years of age. As young people do not initiate tobacco or cannabis at the same time (27,28), we used longitudinal latent class analysis (LLCA) to identify heterogenous classes of individuals with different tobacco and cannabis use profiles across adolescence (29). As a next step we used genetic variants that are separately associated with smoking initiation and lifetime cannabis use to perform one- and two-sample Mendelian randomization (MR) to improve causal inference (30). We expected to find that an earlier age of onset and more frequent use (for both substances) would be associated with larger reductions in cognitive function, and that the MR analyses would demonstrate

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the hypothesised associations between tobacco and cannabis use and diminished cognitive functioning.

METHODS

Observational analyses

Participants and Procedure

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a cohort born in 1991–92. ALSPAC recruited 14,541 pregnant women resident in Avon, UK, with expected dates of delivery between 1 April 1991 and 31 December 1992. The initial number of pregnancies enrolled is 14,541 (for these at least one questionnaire has been returned or a "Children in Focus" clinic had been attended by 19/07/99). Of these initial pregnancies, there was a total of 14,676 foetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. When the oldest children were approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases who had failed to join the study originally. The total sample size for analyses using any data collected after the age of 7 years is therefore 15,454 pregnancies, resulting in 15,589 foetuses. Of this total sample 14,901 were alive at 1 year of age (31–33). Of these, 9,997 offspring were invited to attend the 24-year clinic assessment. A detailed overview of our study population, including attrition at the different measurement occasions is presented in Supplementary Material Figure S1. Detailed information about ALSPAC is available online www.bris.ac.uk/alspac. A fully searchable data dictionary is available on the study's website http://www.bristol.ac.uk/alspac/researchers/our-data/. Approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

was obtained from participants following recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples was collected in accordance with the Human Tissue Act (2004).

Measures

A timeline of data collection is presented in Supplementary Material Figure S2.

Exposure variables

Information on tobacco and cannabis use were collected on six occasions via questionnaire (Q) or during attendance at a study clinic (C). Median ages at response were: 13y(C), 14y(Q), 15y(C) 16y(Q), 17y(C), and 18y(Q).

Tobacco use

Patterns of tobacco use have been described in detail elsewhere (34). Responses to one or more questions at each time point were used to derive a repeated four-level ordinal variable with categories 'Non-smoker', 'Occasional smoker' (typically less than once per week), 'Weekly smoker' and 'Daily smoker'. There was good agreement that a four-class solution was adequate in explaining the heterogeneity in tobacco based on model fit criteria (see Table S1a). The four-class model (*n*=8,525) comprised individuals with a higher probability of 'early-onset regular smokers' (3.4%), 'late-onset regular smokers' (11.6%), 'experimenters' (17.4%), and 'non-smokers' (67.5%) (Figure 1a).

Cannabis use

Patterns of cannabis use have been described in detail elsewhere (35). Responses to one or more questions at each time point were used to derive a repeated three-level ordinal variable with categories 'Do not use', 'Occasional use' (typically less than once per week) and 'Frequent use' (typically once per week or more). There was good agreement that a four-class solution was adequate in explaining the heterogeneity in cannabis use based on

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

model fit criteria (see Table S1b). The four-class model (*n*=8,093) comprised individuals with a higher probability of 'early-onset regular users' (3.6%), 'early-onset occasional users' (2.9%), 'late-onset occasional users' (13.8%), and 'non-users' (79.8%) (Figure 1b).

Outcome variables

At 24 years of age (*M*=24.0 years; *SD*=9.8 months) participants attended a clinic-based assessment which included computerised cognitive assessments as part of a broader assessment battery of mental and physical health and behaviour. Data collection for the online questionnaires was collected and managed by REDcap electronic data capture tools (36,37). Further information on all three cognitive tasks is presented in Supplementary material.

Working memory

The *N*-back task (2-back condition) was used to assess working memory. The *N*-back task (38) is widely used to measure working memory (39–41). A measure of discriminability (*d*') was chosen as the primary outcome measure given it is an overall performance estimate. High scores on *number of hits* indicated more accurate identification, while high scores on *false alarms* indicated less accurate identification. High scores on *d*', therefore, indicated a greater ability to distinguish signal from noise. *d*' data were available for *n*=3,242 participants.

Response inhibition

The Stop Signal Task (42) was used to assess response inhibition – the ability to prevent an ongoing motor response. The task consisted of 256 trials, which included a 4:1 ratio of trials without stop signals to trials with stop signals. Mean response times were calculated. An estimate of *stop signal reaction time* (SSRT) was calculated using the median of the inhibition function approach (43). SSRT used as the primary outcome as it is a reliable

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

measure of inhibitory control, with shorter reaction times indicating faster inhibition. SSRT data were available for 3,201 participants.

Emotion recognition

Emotion recognition was assessed using a six alternative forced choice (6AFC) emotion recognition task (44) comprising of 96 trials (16 for each emotion) which measures the ability to identify emotions in facial expressions that vary in intensity. In each trial, participants were presented with a face displaying one of six emotions: anger, disgust, fear, happiness, sadness, or surprise. Participants were required to select the descriptor that best described the emotion that was present in the face, using the computer mouse. Emotion intensity varied across 8 levels within each emotion from the prototypical emotion to an almost neutral face. Each individual stimulus was presented twice, giving a total of 96 trials. An overall measure of ER (the number of facial emotions accurately identified) was used as the primary outcome. ER data were available for *n*=3,368 participants.

Potential confounders

Confounders comprised of established risk factors for cognitive functioning that could plausibly have a relationship with earlier substance use. Potential confounders included: income, maternal education, socioeconomic position, housing tenure, sex, and maternal smoking during first trimester in pregnancy. Working memory at approximately 11 years and experience of a head injury/unconsciousness up to 11 years were included to control for cognitive functioning prior to baseline measures of substance use. The inclusion of both measures helps to control for the possibility that the onset of substance use is caused by impaired or lower cognitive performance, thereby allowing for the temporal order between substance use and later cognitive functioning to be established. Finally, a measure of alcohol use asking whether they had ever had a whole drink of alcohol was

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

collected at age 13 years (up to the first assessment of smoking and cannabis use). Further information is presented in Supplementary material.

Statistical methods

Different tobacco and cannabis phenotypes were used across different analytic methods.

Observational analyses

Tobacco and cannabis class membership was related to covariates using the Bolck-Croon-Hagenaars (45) method. This approach uses the weights derived from the latent classes to reflect measurement error in the latent class variable. Linear regression was used to examine the association between the cognitive outcomes and latent class membership controlling for the confounding variables. Results are reported as unstandardized beta coefficients with 95% confidence intervals. Analyses were carried out using Mplus 8.4 (46).

Missing data

Missing data was dealt with in three steps. First, full information maximum likelihood (FIML) was used to derive trajectories tobacco (N=8,525) and cannabis (N=8,093) based on individuals who had information on at least one timepoint between 13 and 18 years. For a detailed description of missingness at each timepoint see Tables S2a and S2b. Next, multiple imputation was based on 3,232 participants (for both tobacco and cannabis models) who had information on at least one of the cognitive outcomes. The imputation model (based on 100 datasets) contained performance on all of the cognitive tasks, all measures of tobacco and cannabis use, and potential confounding variables, as well as a number of auxiliary variables known to be related to missingness (e.g., substance use in early adolescence, parental financial difficulties, and other SES variables). Finally, inverse probability weighting was used where estimates of prevalence and associations were

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

weighted to account for probabilities of non-response to attending the clinic. See Table S3 for a detailed description of attrition for completing the cognitive assessments at age 24 years. See Tables S4a and S4b for a detailed description of confounding factors associated with tobacco and cannabis use class membership.

Genetic analyses

Mendelian randomization (MR)

Two-sample MR was used to test the hypothesised causal effect of smoking initiation and lifetime cannabis use on cognitive functioning. The two-sample MR approach requires summary level data from GWAS, enabling SNP-outcome and SNP-exposure effects to be derived from different data sources. As the genetic instrument for smoking we used 378-independent genome-wide significant SNPs associated with smoking initiation identified by the GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN https://gscan.sph.umich.edu/) based on a total sample of ~1,200,000 individuals. We used 8-independent genome-wide significant SNPs associated with lifetime cannabis use based on the largest GWAS to date (*n*=184,765) (47). As outcomes, we used GWAS conducted in ALSPAC (*n*~2,500) for each of our three primary outcome measures: i) working memory assessed using *d'*; ii) response inhibition assessed using SSRT; and iii) emotion recognition assessed using total number of correctly identified emotions (48).

Analyses were performed using the TwoSampleMR R package, part of MR-Base (49). The inverse-variance weighted (IVW) approach was used as a primary analysis, with three complementary estimation methods as sensitivity analyses which each make different assumptions about the nature of horizontal pleiotropy (where the genetic variant associates with the outcome via an independent pathway to the exposure): MR Egger (50), weighted

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

median (51), and weighted mode (52). A consistent effect across all of these methods would provide the most confidence that any observed effects are not due to pleiotropy.

Next, one-sample MR analyses using two-stage least squares (2SLS) regression models with robust standard errors was used to examine the full GRS for smoking initiation (378 SNPs) as an instrument for smoking initiation and cannabis use (8 SNPs) as an instrument for lifetime cannabis use in relation to the three cognitive assessments at 24 years of age. Using individual-level data, the first stage involves regressing tobacco/cannabis use upon individual smoking initiation/lifetime cannabis use SNPs. Lifetime tobacco use (n=1,638/5,107) (32%) up to age 15 years and lifetime cannabis use (n=1,348/5,319) (25%) up to age 24 years were chosen as exposures. Each of the cognitive outcomes were then regressed on the fitted values from the stage 1 for tobacco and cannabis use in the second stage. The three key assumptions in MR are 1) the genetic instrument is robustly associated with the exposure of interest; 2) confounders of the exposure-outcome association are not associated with the genetic instrument; and 3) the genetic instrument is not associated with the outcome other than through its association with the exposure; see (30) for a full description. Power calculations conducted for one-sample MR analyses using mRnd (53) indicated that we had 80% power to detect an effect size of 0.24 for smoking initiation and 0.15 for lifetime cannabis use using a sample size of n~3,300 (individuals who had available cognitive data in ALSPAC).

RESULTS

Observational analyses

Working memory – 2-back task

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Unadjusted and adjusted associations between patterns of tobacco/cannabis use from 13 to 18 years and working memory at age 24 are presented in Tables 1a and 1b. There was evidence to suggest that late-onset regular smokers (*b*=-0.29, 95%CI=-0.45 to -0.13) and earl-onset regular smokers (*b*=-0.45, 95%CI=-0.84 to -0.05) showed poorer working memory performance compared to the non-smokers in the fully adjusted model. There was also evidence indicating that early-onset regular cannabis users showed poorer working memory performance compared to the non-cannabis users in the fully adjusted model (*b*=-0.62, 95%CI=-0.93 to -0.31). In the sensitivity analyses, there was some evidence to suggest that early-onset regular tobacco smoking was associated with fewer correct hits on the N-back task in the fully adjusted models (Table S5a).

[Tables 1a and 1b]

Response inhibition - stop signal task

Unadjusted and adjusted associations between patterns of tobacco/cannabis use from 13 to 18 years and response inhibition at age 24 are presented in Tables 2a and 2b. The fully adjusted models suggest slower SSRT (indicative of impaired response inhibition) in early-onset regular smokers (*b*=0.18, 95%CI=0.07 to 0.28), and early-onset regular cannabis users (*b*=0.30, 95%CI=0.08 to 0.52) compared to tobacco and cannabis non-users. All associations were supported by significant Wald test values indicating a significant difference between the groups in terms of their ability to inhibit responses. In the sensitivity analyses, there was evidence to suggest that late-onset regular tobacco and early-onset cannabis users were associated with worse Go and Stop accuracy in the fully adjusted models (Tables S6a and S6b).

[Tables 2a and 2b]

Emotion recognition – 6AFC task

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Unadjusted and adjusted associations between patterns of tobacco/cannabis use from 13 to 18 years and emotion recognition at age 24 are presented in Tables 3a and 3b. There was evidence to suggest that late-onset regular smokers (*b*=-0.02, 95%CI=-0.03 to -0.00), and early-onset regular (*b*=-0.04, 95%CI=-0.08 to -0.01) showed poorer emotion recognition compared to non-smokers in the fully adjusted models. There was insufficient evidence of an association between other patterns of tobacco/cannabis use and emotion recognition. There was some evidence in the sensitivity models to suggest late-onset regular tobacco users had poorer ability to identify 'fear' and 'surprise', while early-onset regular tobacco users had poorer ability to identify 'sad' in the fully adjusted models (Table S7d). Early- and late-onset occasional cannabis users had better ability to identify 'anger' and 'disgust', while late-onset occasional cannabis users had poorer ability to identify 'happy' in the fully adjusted models (Table 8d).

[Tables 3a and 3b]

Genetic analyses

Information testing whether the genetic instruments are associated with the confounders are presented in the Supplementary Material (Tables S9a and S9b).

Two-sample Mendelian randomization

Two-sample MR methods provided little evidence to suggest that SNPs associated with smoking initiation were a causal risk factor for deficits in cognitive functioning (Table S4a). Focusing on the IVW estimate as the primary measure, SNPs associated with smoking initiation were not associated with working memory (*b*=-0.02 95%CI=-0.20 to 0.15; *p*=0.52); response inhibition (*b*=-0.06 95%CI=-0.24 to 0.12; *p*=0.31); or emotion recognition (*b*=0.00 95%CI=-0.18 to 0.18; *p*=0.97). Other sensitivity estimates tended to be in the same direction

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

and failed to demonstrate smoking initiation as a causal risk factor for deficits in cognitive functioning.

Similarly, there was little evidence to suggest that SNPs associated with lifetime cannabis use was a causal risk factor for deficits in cognitive functioning (Table S4b). Focusing on the IVW estimate as the primary measure, SNPs associated with lifetime cannabis use were not associated with working memory (*b*=0.28 95%CI=-0.16 to 0.70; *p*=0.21); response inhibition (*b*=-0.13 95%CI=-0.47 to 0.22; *p*=0.47); or emotion recognition (*b*=-0.08 95%CI=-0.52 to 0.36; *p*=0.71). All other sensitivity estimates were in the same direction and failed to demonstrate cannabis use as a causal risk factor for deficits in cognitive functioning.

[Tables 4a and 4b]

One-sample Mendelian randomization

Results from the one-sample MR provided little evidence to suggest that smoking initiation or lifetime cannabis use were causal risk factors for deficits in cognitive functioning (Table 5). SNPs associated with smoking initiation were not associated with working memory (*b*=0.01 95%CI=-0.06 to 0.29; *p*=0.21); response inhibition (*b*=0.16 95%CI=-0.03 to 0.35; *p*=0.10); or emotion recognition (*b*=0.00 95%CI=-0.18 to 0.18; *p*=0.97). Similarly, SNPs associated with lifetime cannabis use were not associated with working memory (*b*=-0.37 95%CI=-0.72 to -0.02; *p*=0.04); response inhibition (*b*=0.04 95%CI=-0.32 to 0.39; *p*=0.85); or emotion recognition (*b*=-0.08 95%CI=-0.52 to 0.36; *p*=0.71).

[Table 5]

DISCUSSION

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

This observational study provided evidence to suggest an association between tobacco and cannabis use across adolescence and cognitive functioning at age 24. Late-onset regular smokers and early-onset regular cannabis users had poorer working memory performance, slower ability to inhibit responses, and poorer ability to recognise emotions compared to the non-smokers and non-cannabis users. Our results remained largely consistent when controlling for prior measures of substance use and cognition allowing for clear temporality between exposure and outcomes. Genetic analyses were imprecise and did not provide clear evidence to suggest that smoking initiation and lifetime cannabis use were causally related to cognitive functioning in the ALSPAC sample. It is likely that these analyses were underpowered.

Comparison with previous studies

To our knowledge, this is the first study to assess the relationship between tobacco and cannabis use, and subsequent cognitive functioning using a combination of observational and genetic epidemiological approaches. Overall, we found an adverse associations between tobacco/cannabis use and working memory, response inhibition, and emotion recognition in ALSPAC, in that those who initiated use at earlier and later ages, and in those with more frequent use. These findings contribute to a literature of mixed findings regarding the direction of association between tobacco and cannabis exposure and subsequent cognition by suggesting that adolescent tobacco and cannabis use precede observed reductions in cognitive function. These findings support studies that have demonstrated effects may depend on the frequency, duration, and age at onset of use (20,21,54–59).

Our study extends previous findings in a number of ways. First, the observational study was better powered than most of the previous studies as it used data from over 3,200

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

participants providing information spanning birth to 24 years of age. Second, identifying heterogeneous patterns of tobacco and cannabis use across this crucial period allows individuals who follow markedly different developmental trajectories to be captured (27,28). Third, the cognitive measures were assessed at a time when they are expected to have reached maturity (2–5), in comparison to previous studies which have examined cognitive functioning at earlier ages while they are still maturing. Examining mature levels of cognitive functioning reduces the possibility that cognitive functioning is influencing earlier tobacco and cannabis use, effects that cannot be disentangled in purely cross-sectional studies. Further, our ability to control for earlier measures of cognitive functioning and substance use, prior to the baseline measures of tobacco and cannabis use helps to rule out the possibility of reverse causation. Fourth, our study sought to examine specificity in cognitive functioning, by using well-validated tests to probe different domains of cognitive functioning instead of focusing on general intelligence. Finally, we sought to triangulate our results by using one- and two-sample MR approaches to assess tobacco and cannabis use as causal risk factors for cognitive functioning. This approach can help to overcome the main sources of bias from classical observational approaches, by providing a more reliable estimate of the likely underlying causal relationship.

Limitations

There are limitations to this study that should be considered. First, the ALSPAC cohort suffers from attrition, which is higher among the socially disadvantaged (60). We attempted to minimize the effect of drop-out by using multiple imputation, FIML, and inverse probability weighting which assume MAR missing patterns. Although it is not possible to test the MAR assumption, it was made more plausible as a number of SES variables were found to predict whether participants attended the clinic or not (Table S1).

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Second, tobacco and cannabis use were self-reported. However, there is evidence to suggest that self-reported assessments are reliable and valid methods (61), and the assessment of tobacco and cannabis use yearly over 6 years in a latent variable framework helps to account for measurement error (62). Third, it is likely that both the one- and two-sample MR analyses are underpowered. However, findings using weak instruments tend to bias findings towards the null in the two-sample setting and toward the outcome-risk association in the one-sample setting (63). Finally, it is possible that the direction of the association could work in both ways, that is, impairments in cognitive functioning may precede (and increase the risk of developing) tobacco and cannabis use (21,64–66). We were able to include a number of measures to maximize the robustness of our findings: (i) ascertaining the temporal order of exposures and outcomes; (ii) controlling for premorbid working memory and brain insults prior to measures of tobacco/cannabis use helped to reduce the possibility of cognitive impairments, or lower cognitive abilities in childhood, influencing tobacco/cannabis use; and (iii) it is possible that a common risk factor is influencing both tobacco/cannabis use and lower cognitive function, however MR methods helps to protect against this possibility by minimizing bias from reverse causation and residual confounding.

Implications and conclusions

Using a triangulation approach of three separate methods, each with different limitations and potential sources of bias, our study contributes to the understanding of the relationship between adolescent tobacco and cannabis use, and subsequent cognitive functioning. Overall, there was observational evidence that adolescent tobacco and cannabis use were associated with subsequent cognitive functioning, highlighting impairments in a range of cognitive domains, including working memory, response

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

inhibition and emotion recognition. Our findings lend support to the developmental vulnerability hypothesis, in that, tobacco and cannabis use in adolescence, when the brain is undergoing critical development, may have neurotoxic effects. Better powered genetically informed studies are required to determine whether these associations are causal.

Acknowledgements: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The work was undertaken with the support of the MRC and Alcohol Research UK (grant number MR/L022206/1). We acknowledge also support from The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer); a UKCRC Public Health Research Centre of Excellence (joint funding (grant number MR/KO232331/1) from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the Welsh Government and the Wellcome Trust, under the auspices of the UK Clinical Research Collaboration); and the NIHR School of Public Health Research. Support was also provided by the UK Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MM_UU_00011/7). LM, RW, SS, and MRM are members of the UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research Centre of Excellence. LM, REW, SS, and MRM are supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol (BRC-1215-20011) and we acknowledge support from NIHR HPRU in Evaluation. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Liam

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Mahedy and Marcus Munafò will serve as guarantors for the contents of this paper. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. GWAS data were generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).

Disclosures: CS is employed by Cambridge Cognition. MRM is co-director of Jericoe Ltd, which produces software for the assessment and modification of emotion recognition. LM, RW, SS, MF, JH, & MH report no conflicts of interest.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

REFERENCES

1. De Bellis MD, Clark DB, Beers SR, Soloff PH, Boring AM, Hall J, et al. Hippocampal volume in adolescent-onset alcohol use disorders. Am J Psychiatry. 2000;157(5):737–44.

2. Fry AF, Hale S. Relationships among processing speed, working memory, and fluid intelligence in children. Biol Psychol. 2000;54(1–3):1–34.

3. Kramer AF, de Sather JCMG, Cassavaugh ND. Development of attentional and oculomotor control. Dev Psychol. 2005;41(5):760–72.

4. Davidson MC, Amso D, Anderson LC, Diamond A. Development of cognitive control and executive functions from 4 to 13 years: evidence from manipulations of memory, inhibition, and task switching. Neuropsychologia. 2006;44(11):2037–78.

5. Thomas LA, De Bellis MD, Graham R, LaBar KS. Development of emotional facial recognition in late childhood and adolescence. Dev Sci. 2007;10(5):547–58.

6. Sowell ER, Delis D, Stiles J, Jernigan TL. Improved memory functioning and frontal lobe maturation between childhood and adolescence: a structural MRI study. J Int Neuropsychol Soc. 2001;7(3):312–22.

7. Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post-adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999;2:859.

8. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):371–82.

9. Newman LA, McGaughy J. Cholinergic deafferentation of prefrontal cortex increases sensitivity to cross-modal distractors during a sustained attention task. J Neurosci. 2008;28(10):2642–50.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

10. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186–93.

11. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol. 2008;286(1-2 Suppl 1):S108-13.

12. Slotkin TA. Cholinergic systems in brain development and disruption by neurotoxicants: nicotine, environmental tobacco smoke, organophosphates. Toxicol Appl Pharmacol. 2004;198(2):132–51.

13. Dwyer JB, Broide RS, Leslie FM. Nicotine and brain development. Birth Defects Res C Embryo Today. 2008;84(1):30–44.

14. Gonzalez R, Pacheco-Colón I, Duperrouzel JC, Hawes SW. Does cannabis use cause declines in neuropsychological functioning? A review of longitudinal studies. J Int Neuropsychol Soc. 2017;23(9–10):893–902.

15. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ. 2002;166(7):887–91.

16. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, et al. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci U S A. 2016;113(5):E500-8.

17. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction. 2011;106(12):2195–203.

18. Jacobus J, Squeglia LM, Meruelo AD, Castro N, Brumback T, Giedd JN, et al. Cortical thickness in adolescent marijuana and alcohol users: A three-year prospective study from adolescence to young adulthood. Dev Cogn Neurosci. 2015;16:101–9.

19. Mokrysz C, Landy R, Gage SH, Munafò MR, Roiser JP, Curran H V. Are IQ and

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol. 2016;30(2):159–68.

20. Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, et al. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction. 2018;113(2):257–65.

21. Castellanos-Ryan N, Pingault J-B, Parent S, Vitaro F, Tremblay RE, Seguin JR. Adolescent cannabis use, change in neurocognitive function, and high-school graduation: A longitudinal study from early adolescence to young adulthood. Dev Psychopathol. 2017;29(4):1253–66.

22. Morin J-FG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O'Leary-Barrett M, et al. A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry. 2018;176(2):98–106.

23. Slotkin TA. Nicotine and the adolescent brain: insights from an animal model. Neurotoxicol Teratol. 2002;24(3):369–84.

24. Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. Neuroscience. 2007;144(4):1347–60.

25. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of cigarette smoking in young adults--a comparison with pre-drug performance. Neurotoxicol Teratol. 2006;28(4):517–25.

26. Weiser M, Zarka S, Werbeloff N, Kravitz E, Lubin G. Cognitive test scores in male adolescent cigarette smokers compared to non-smokers: a population-based study. Addiction. 2010;105(2):358–63.

27. Chen K, Kandel D. The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health. 1995;85(1):41–7.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

28. Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med. 2008;5(7):e141–e141.

29. Lubke GH, Muthén B. Investigating population heterogeneity with factor mixture models. Psychol Methods. 2005;10(1):21–39.

30. Lawlor D, Richmond R, Warrington N, McMahon G, Davey Smith G, Bowden J, et al. Using Mendelian randomization to determine causal effects of maternal pregnancy (intrauterine) exposures on offspring outcomes: Sources of bias and methods for assessing them. Wellcome open Res. 2017;2:11.

31. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42(1):111–27.

32. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et al. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013;42(1):97–110.

33. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et al. The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019. Wellcome Open Res. 2019;4:51.

34. Howe LJ, Trela-Larsen L, Taylor M, Heron J, Munafo MR, Taylor AE. Body mass index, body dissatisfaction and adolescent smoking initiation. Drug Alcohol Depend. 2017 Sep;178:143–9.

35. Taylor M, Collin SM, Munafo MR, MacLeod J, Hickman M, Heron J. Patterns of cannabis use during adolescence and their association with harmful substance use behaviour: findings from a UK birth cohort. J Epidemiol Community Health. 2017

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Aug;71(8):764–70.

36. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.

37. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95(5):103208.

38. Kirchner WK. Age differences in short-term retention of rapidly changing information. J Exp Psychol. 1958;55(4):352–8.

39. Wardle MC, de Wit H, Penton-Voak I, Lewis G, Munafo MR. Lack of association between COMT and working memory in a population-based cohort of healthy young adults. Neuropsychopharmacology. 2013;38(7):1253–63.

40. Rossi R, Zammit S, Button KS, Munafò MR, Lewis G, David AS. Psychotic experiences and working memory: a population-based study using signal-detection analysis. PLoS One. 2016;11(4):e0153148–e0153148.

41. Mahedy L, Field M, Gage S, Hammerton G, Heron J, Hickman M, et al. Alcohol use in adolescence and later working memory: Findings from a large population-based birth cohort. Alcohol Alcohol. 2018;53:251–8.

42. Logan GD, Cowan WB, Davis KA. On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform. 1984;10(2):276–91.

43. Band GPH, van der Molen MW, Logan GD. Horse-race model simulations of the stop-signal procedure. Acta Psychol (Amst). 2003;112(2):105–42.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

44. Penton-Voak IS, Bate H, Lewis G, Munafo MR. Effects of emotion perception training on mood in undergraduate students: randomised controlled trial. Br J Psychiatry. 2012;201(1):71–2.

45. Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical variables: one-step versus three-step estimators. Polit Anal. 2004;12(1):3–27.

46. Muthén LK, Muthén BO. User's Guide. 7th ed. Muthén LK, Muthén BO, editors. Los Angeles, CA: Muthén & Muthén; 2016.

47. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 2018;21(9):1161–70.

48. Mahedy L, Suddell S, Skirrow C, Wootton R, Fernandes GS, Heron J, et al. Alcohol use and cognitive functioning in young adults: an observational and Mendelian randomisation study. medRxiv. 2019;19003327.

49. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018 May;7.

50. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.

51. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14.

52. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

2017;46(6):1985–98.

53. Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2012;42(5):1497–501.

54. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–7.

55. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WDS. Age of onset of marijuana use impacts inhibitory processing. Neurosci Lett. 2012;511(2):89–94.

56. Mashhoon Y, Betts J, Farmer SL, Lukas SE. Early onset tobacco cigarette smokers exhibit deficits in response inhibition and sustained attention. Drug Alcohol Depend. 2018;184:48–56.

57. Goriounova NA, Mansvelder HD. Short- and long-term consequences of nicotine exposure during adolescence for prefrontal cortex neuronal network function. Cold Spring Harb Perspect Med. 2012;2(12):a012120–a012120.

58. Mokrysz C, Freeman TP, Korkki S, Griffiths K, Curran H V. Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Transl Psychiatry. 2016;6(11):e961–e961.

59. Boccio CM, Beaver KM. Examining the influence of adolescent marijuana use on adult intelligence: Further evidence in the causation versus spuriousness debate. Drug Alcohol Depend. 2017;177:199–206.

60. Wolke D, Waylen A, Samara M, Steer C, Goodman R, Ford T, et al. Selective drop-out in longitudinal studies and non-biased prediction of behaviour disorders. Br J Psychiatry. 2009;195(3):249–56.

61. Boykan R, Messina CR, Chateau G, Eliscu A, Tolentino J, Goniewicz ML. Self-reported

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

use of tobacco, E-cigarettes, and marijuana versus urinary biomarkers. Pediatrics. 2019;143(5).

62. Bray BC, Lanza ST, Tan X. Eliminating bias in classify-analyze approaches for latent class analysis. Struct Equ Model. 2015;22(1):1–11.

63. Davies NM, Holmes M V, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

64. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Effect of baseline cannabis use and working-memory network function on changes in cannabis use in heavy cannabis users: A prospective fMRI study. Hum Brain Mapp. 2014;35(5):2470–82.

65. Squeglia LM, Jacobus J, Nguyen-Louie TT, Tapert SF. Inhibition during early adolescence predicts alcohol and marijuana use by late adolescence. Neuropsychology. 2014;28(5):782–90.

66. Anokhin AP, Golosheykin S. Neural Correlates of Response Inhibition in Adolescents Prospectively Predict Regular Tobacco Smoking. Dev Neuropsychol. 2016;41(1–2):22–37.



Figure 1a. Distribution of tobacco use across latent classes at each timepoint (*n*=8,525). Class proportions based on estimated posterior probability[1].

[1] Tobacco use at age 13 was omitted from the figure as 'daily smoking' was not recorded at this age. Overall, the 'non-users' reported a low probability of tobacco use across all measurement occasions; 'experimenters' were mostly characterised by smoking on the later measurement occasions only; 'late-onset regular' smokers were mostly characterised by smoking on a daily basis in the later measurement occasions only; while 'early-onset regular' smokers were mostly characterised by smoking on a daily basis across timepoints from age 14 years onwards.



Figure 1b. Distribution of cannabis use across latent classes at each timepoint (*n*=8,093). Class proportions based on estimated posterior probability[2].

[2] The 'non users' reported a low probability of cannabis use across all measurement occasions; 'late-onset occasional' cannabis users were mostly characterised by cannabis use on the later measurement occasions only; 'early-onset occasional' cannabis users were mostly characterised by occasional cannabis use across all measurements; while 'regular cannabis users' were mostly characterised by cannabis use across timepoints with increasing involvement from age 15 years onwards.

Table 1a. Smoking patterns from 13 to 18 years and working memory at age 24 (higher *d'* scores reflect better performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
n=3,232 for all models	Reference group	*b* (95% CI)	*b* (95% CI)	*b* (95% CI)	Wald (df) *p* value
Unadjusted models					
Working memory *d'*	-	0.01 (-0.10, 0.10)	-0.32 (-0.48, -0.16)	-0.50 (-0.89, -0.10)	28.92 (3) p<0.001
Adjusted for SES					
Working memory *d'*	-	0.00 (-0.11, 0.11)	-0.28 (-0.44, -0.12)	-0.39 (-0.78, 0.01)	19.78 (3) p<0.001
Adjusted for SES/WM/HI					
Working memory *d'*	-	0.01 (-0.10, 0.11)	-0.27 (-0.43, -0.11)	-0.42 (-0.81, -0.02)	20.25 (3) p<0.001
Fully adjusted models					
Working memory *d'*	-	0.01 (-0.12, 0.10)	-0.29 (-0.45, -0.13)	-0.45 (-0.84, -0.05)	22.12 (3) p<0.001

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 1b. Patterns of cannabis use from 13 to 18 years and working memory at age 24 (lower *d'* reflect poorer performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
n=3,232 for all models	Reference group	*b* (95% CI)	*b* (95% CI)	*b* (95% CI)	Wald (df) *p* value
Unadjusted models					
Working memory *d'*	-	-0.01 (-0.13, 0.12)	0.24 (-0.05, 0.52)	-0.58 (-0.90, -0.26)	14.10 (3) p=0.003
Adjusted for SES					
Working memory *d'*	-	-0.06 (-0.18, 0.07)	0.17 (-0.11, 0.45)	-0.60 (-0.91, -0.30)	16.26 (3) p<0.001
Adjusted for SES/WM/HI					
Working memory *d'*	-	-0.09 (-0.21, 0.04)	0.15 (-0.12, 0.43)	-0.60 (-0.91, -0.30)	17.64 (3) p<0.001
Fully adjusted models					
Working memory *d'*	-	-0.10 (-0.22, 0.03)	0.12 (-0.17, 0.41)	-0.62 (-0.93, -0.31)	18.56 (3) p<0.001

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 2a. Smoking patterns from 13 to 18 years and response inhibition at age 24 (shorter reaction times reflect better performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
n=3,232 for all models	Reference group	*b* (95% CI)	*b* (95% CI)	*b* (95% CI)	Wald (df) *p* value
Unadjusted models					
Stop signal reaction time	-	0.02 (-0.05, 0.09)	0.19 (-0.02, 0.40)	0.21 (0.10, 0.31)	22.73 (3) p<0.001
Adjusted for SES					
Stop signal reaction time	-	0.01 (-0.06, 0.09)	0.08 (-0.13, 0.30)	0.18 (0.07, 0.28)	13.04 (3) p=0.005
Adjusted for SES/WM/HI					
Stop signal reaction time	-	0.01 (-0.06, 0.08)	0.10 (-0.12, 0.32)	0.17 (0.07, 0.27)	13.05 (3) p=0.005
Fully adjusted model					
Stop signal reaction time	-	0.01 (-0.06, 0.09)	0.10 (-0.12, 0.32)	0.18 (0.07, 0.28)	12.78 (3) p=0.005

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; positive estimates indicate poorer performance

Table 2b. Patterns of cannabis use from 13 to 18 years and response inhibition at age 24 (longer reaction times reflect poorer performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
n=3,232 for all models	Reference group	*b* (95% CI)	*b* (95% CI)	*b* (95% CI)	Wald (df) *p* value
Unadjusted models					
Stop signal reaction time	-	0.00 (-0.07, 0.08)	0.03 (-0.13, 0.18)	0.29 (0.06, 0.52)	7.02 (3) p=0.07
Adjusted for SES					
Stop signal reaction time	-	0.02 (-0.06, 0.10)	0.04 (-0.13, 0.20)	0.30 (0.07, 0.52)	8.03 (3) p=0.04
Adjusted for SES/WM/HI					
Stop signal reaction time	-	0.04 (-0.04, 0.11)	0.04 (-0.12, 0.21)	0.30 (0.08, 0.52)	9.25 (3) p=0.02
Fully adjusted model					
Stop signal reaction time	-	0.04 (-0.04, 0.11)	0.05 (-0.11, 0.22)	0.30 (0.08, 0.52)	9.24 (3) p=0.02

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 3a. Smoking patterns from 13 to 18 and emotion recognition at age 24 (lower scores reflect poorer performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
n=3,232 for all models	Reference group	*b* (95% CI)	*b* (95% CI)	*b* (95% CI)	Wald (df) *p* value
Unadjusted models					
Total hits	-	0.00 (-0.01, 0.01)	-0.02 (-0.04, -0.01)	-0.05 (-0.08, -0.01)	20.32 (3) p<0.001
Adjusted for SES					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.07, -0.01)	14.45 (3) p=0.002
Adjusted for SES/WM/HI					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.08, -0.01)	14.65 (3) p=0.002
Fully adjusted model					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.08, -0.01)	16.43 (3) p=0.001

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 3b. Patterns of cannabis use from 13 to 18 and emotion recognition at age 24 (higher scores reflect better performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
n=3,232 for all models	Reference group	*b* (95% CI)	*b* (95% CI)	*b* (95% CI)	Wald (df) *p* value
Unadjusted models					
Total hits	-	0.00 (-0.01, 0.02)	0.03 (0.00, 0.06)	-0.03 (-0.06, 0.00)	7.71 (3) p=0.05
Adjusted for SES					
Total hits	-	0.00 (-0.01, 0.01)	0.03 (0.00, 0.05)	-0.02 (-0.05, 0.01)	4.68 (3) p=0.20
Adjusted for SES/WM/HI					
Total hits	-	-0.00 (-0.01, 0.01)	0.03 (-0.00, 0.05)	-0.02 (-0.05, 0.01)	4.50 (3) p=0.21
Fully adjusted model					
Total hits	-	-0.00 (-0.01, 0.01)	0.02 (-0.00, 0.05)	-0.02 (-0.05, 0.01)	4.23 (3) p=0.24

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table S4a. Two-sample MR analyses of the effects of smoking initiation on cognitive functioning (unstandardized coefficients)

Exposure	Outcome	Method	N SNPs	Beta (95% CI)	P-value
Smoking initiation	**Working memory**	Inverse-Variance Weighted	341	0.01 (-0.06, 0.29)	0.21
		MR Egger (SIMEX)	341	-0.68 (-1.41, 0.06)	0.07
		Weighted Median	341	0.06 (-0.21, 0.32)	0.65
		Weighted Mode	341	-0.32 (-1.11, 0.48)	0.43
Smoking initiation	**Response inhibition**	Inverse-Variance Weighted	341	0.16 (-0.03, 0.35)	0.10
		MR Egger (SIMEX)	341	1.30 (-2.22, 0.03)	0.02
		Weighted Median	341	0.21 (-0.07, 0.49)	0.14
		Weighted Mode	341	0.30 (-0.55, 1.16)	0.49
Smoking initiation	**Emotion recognition**	Inverse-Variance Weighted	341	0.00 (-0.18, 0.18)	0.97
		MR Egger (SIMEX)	341	0.04 (-0.71, 0.79)	0.91
		Weighted Median	341	-0.05 (-0.31, 0.21)	0.68
		Weighted Mode	341	-0.19 (-1.04, 0.67)	0.67

Table S4b. Two-sample MR analyses of the effects of lifetime cannabis use on cognitive functioning (unstandardized coefficients)

Exposure	Outcome	Method	N SNPs	Beta (95% CI)	P-value
Lifetime cannabis use	**Working memory**	Inverse-Variance Weighted	8	-0.37 (-0.72, -0.02)	0.04
		MR Egger (SIMEX)	8	-0.10 (-0.21, 0.03)	0.17
		Weighted Median	8	-0.38 (-0.81, 0.06)	0.09
		Weighted Mode	8	-0.21 (-0.85, 0.43)	0.55
Lifetime cannabis use	**Response inhibition**	Inverse-Variance Weighted	8	0.04 (-0.32, 0.39)	0.85
		MR Egger (SIMEX)	8	0.50 (-0.22, 0.02)	0.32
		Weighted Median	8	0.22 (-0.24, 0.68)	0.35
		Weighted Mode	8	0.26 (-0.35, 0.87)	0.43
Lifetime cannabis use	**Emotion recognition**	Inverse-Variance Weighted	8	-0.08 (-0.52, 0.36)	0.71
		MR Egger (SIMEX)	8	0.06 (-0.22, 0.03)	0.93
		Weighted Median	8	0.02 (-0.46, 0.48)	0.95
		Weighted Mode	8	0.01 (-0.67, 0.69)	0.98

medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20028274; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 5. One-sample MR analyses of the effects of smoking initiation on cognitive functioning (standardised coefficients)

	β	se	95% CI	*p*	F statistic
Smoking initiation					
Working memory	-0.38	0.58	-1.51, 0.75	0.51	14.63
Response inhibition	-0.27	0.53	-1.31, 0.77	0.61	18.12
Emotion recognition	-0.53	0.54	-1.59, 0.53	0.33	17.57
Lifetime cannabis use					
Working memory	-1.41	0.97	-3.31, 0.49	0.14	6.70
Response inhibition	0.02	0.68	-1.31, 1.35	0.98	8.87
Emotion recognition	-0.04	0.69	-1.35, 1.27	0.95	8.79